URN:NBN:SI:doc-A2HWJPWT2024Bratkovič, Tomaždocuments/doc/A/URN_NBN_SI_doc-A2HWJPWT_001.pdfdocuments/doc/A/URN_NBN_SI_doc-A2HWJPWT_001.txt275articlestr. 120-1290014-8229196220163URN:NBN:SI:doc-A2HWJPWTslvSlovensko farmacevtsko društvoFarmacevtski vestnikInCalemtuzumabanti-CD20 monoclonal antibodiesBiološka zdravilaglatiramerinterferon betamonoklonska protitelesa proti CD20Multipla sklerozamultiple sclerosisnatalizumabBiološka zdravila za zdravljenje multiple sklerozeBiologicals for the treatment of multiple sclerosis